Combining Therapeutic Antibodies Using Basiliximab and Etanercept for Severe Steroid-Refractory Acute Graft-Versus-host Disease: A Multi-Center Prospective Study
Yamin Tan,Haowen Xiao,Depei Wu,Yi Luo,Jianping Lan,Qifa Liu,Kang Yu,Jimin Shi,Jingsong He,Weiyan Zheng,Xiaoyu Lai,Yuanyuan Zhu,Kaili Du,Yishan Ye,Yanmin Zhao,Gaofeng Zheng,Yongxian Hu,Xiaoyan Han,Yanlong Zheng,Guoqing Wei,Zhen Cai,He Huang
DOI: https://doi.org/10.1080/2162402x.2016.1277307
2017-01-01
OncoImmunology
Abstract:Acute graft versus host disease (aGVHD) remains a major problem after allogeneic hematopoietic stem cell transplantation. Standard frontline therapy for aGVHD involves corticosteroids. However, fewer than half of patients have a lasting complete response. The long-term mortality rate of steroid-refractory aGVHD (SR-aGVHD) remains around 70%. To date, no consensus has been reached regarding the optimal salvage treatment for SR-aGVHD. We performed the first prospective, multi-center clinical trial to assess the efficacy and safety of a novel approach to treat severe (grades III–IV) SR-aGVHD with the combination of basiliximab and etanercept. Sixty-five patients with severe SR-aGVHD from six centers were included. The median number of basiliximab infusions was 4 (range 2–11) and of etanercept was 9 (range 2–12). At day 28 after starting the combination treatment, overall response (complete and partial response: CR+PR) to second-line treatment was 90.8% with 75.4% being CR. The incidences of CR per organ were 100%, 73.8%, and 79.7% for skin, liver, and gut involvement, respectively. Patients >30-y old (p = 0.043, RR = 3.169), development of grades III–IV liver aGVHD (p = 0.007, RR = 5.034) and cytomegalovirus (CMV) reactivation (p = 0.035, RR = 4.02) were independent predictors for incomplete response. Combined treatment with basiliximab and etanercept resulted in improved CR to visceral aGVHD and significantly superior 2-y overall survival (54.7% vs. 14.8%, p <0.001) compared with classical salvage treatments. Our data suggest that the combination of basiliximab and etanercept may constitute a promising new treatment option for SR-aGVHD.